Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 2007 results for nice guidelines

  1. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 February 2025

    Sections for TA1037

  2. Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

    NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency

    Medtech innovation briefing
    Published
    30 September 2015

  3. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.

    Technology appraisal guidance
    Published
    25 September 2024

    Sections for TA1008

  4. Inditherm patient warming mattress for the prevention of inadvertent hypothermia (MTG7)

    In March 2018, NICE reviewed this guidance and recommended it should be withdrawn as it has been updated and replaced by the NICE guideline on hypothermia: prevention and management in adults having surgery. For a copy of the review decision please contact nice@nice.org.uk.

    Withdrawn guidance

  5. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

    Withdrawn guidance

  6. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Withdrawn guidance

  7. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Withdrawn guidance

  8. Stretta System for gastro-oesophageal reflux disease (MIB74)

    NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease

    Medtech innovation briefing
    Published
    26 July 2016

  9. Transperineal biopsy for diagnosing prostate cancer (HTG680)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.

    HealthTech guidance
    Published
    1 June 2023
    View recommendations

    Sections for HTG680

  10. Natural Cycles for monitoring fertility (MIB244)

    NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .

    Medtech innovation briefing
    Published
    19 January 2021

  11. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  12. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  13. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  14. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  15. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance